Alnylam Pharmaceuticals Inc
NASDAQ:ALNY

Watchlist Manager
Alnylam Pharmaceuticals Inc Logo
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Watchlist
Price: 245.44 USD 2.75% Market Closed
Market Cap: 31.7B USD
Have any thoughts about
Alnylam Pharmaceuticals Inc?
Write Note

Alnylam Pharmaceuticals Inc
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Alnylam Pharmaceuticals Inc
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Accounts Receivables
$289.3m
CAGR 3-Years
35%
CAGR 5-Years
43%
CAGR 10-Years
93%
Abbvie Inc
NYSE:ABBV
Accounts Receivables
$11.5B
CAGR 3-Years
7%
CAGR 5-Years
16%
CAGR 10-Years
12%
Gilead Sciences Inc
NASDAQ:GILD
Accounts Receivables
$4.6B
CAGR 3-Years
0%
CAGR 5-Years
7%
CAGR 10-Years
5%
Amgen Inc
NASDAQ:AMGN
Accounts Receivables
$7.3B
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
12%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accounts Receivables
$1.8B
CAGR 3-Years
17%
CAGR 5-Years
32%
CAGR 10-Years
31%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accounts Receivables
$6.1B
CAGR 3-Years
4%
CAGR 5-Years
18%
CAGR 10-Years
21%
No Stocks Found

Alnylam Pharmaceuticals Inc
Glance View

Market Cap
31.6B USD
Industry
Biotechnology
Economic Moat
Narrow

In the heart of the biotechnology revolution, Alnylam Pharmaceuticals Inc. has been a pioneering force, transforming the landscape of medicine through its innovative use of RNA interference (RNAi) technology. Founded in 2002 and based in Cambridge, Massachusetts, the company set out on a bold mission to silence disease-causing genes by targeting RNA, the intermediary that carries genetic instructions necessary for protein synthesis. This groundbreaking approach diverges from traditional methods that focus on targeting proteins directly and instead intervenes earlier in the disease process to eliminate or reduce the proteins before they can wreak havoc on the body. Fueled by extensive research and a robust pipeline, Alnylam has successfully brought several RNAi-based therapies to market, such as Onpattro and Givlaari, which address rare genetic disorders with high unmet medical needs. Alnylam's business model is centered around the commercial success of its novel therapies, partnerships with other pharmaceutical giants, and strategic collaborations for global distribution. By securing alliances with industry leaders like Sanofi and Regeneron, Alnylam has been able to expand its research capabilities and broaden its market reach. Revenue for the company is primarily driven by the sales of its approved products, which continue to grow as they gain acceptance within the medical community. Additionally, Alnylam's extensive patent portfolio and its strategic licensing agreements provide an additional revenue stream, safeguarding its innovations and ensuring it retains a competitive edge in this rapidly advancing field. Through its relentless pursuit of innovation, Alnylam continues to position itself as a trailblazer in turning the once theoretical promise of RNAi into a clinical reality.

ALNY Intrinsic Value
176.11 USD
Overvaluation 28%
Intrinsic Value
Price

See Also

What is Alnylam Pharmaceuticals Inc's Accounts Receivables?
Accounts Receivables
289.3m USD

Based on the financial report for Sep 30, 2024, Alnylam Pharmaceuticals Inc's Accounts Receivables amounts to 289.3m USD.

What is Alnylam Pharmaceuticals Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
93%

Over the last year, the Accounts Receivables growth was 38%. The average annual Accounts Receivables growth rates for Alnylam Pharmaceuticals Inc have been 35% over the past three years , 43% over the past five years , and 93% over the past ten years .

Back to Top